PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT05960032
- Locations
- 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China
A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Estraimod Immediate Release (IR)
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT05956002
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Completed
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 275
- Registration Number
- NCT05954546
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT05948085
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 514
- Registration Number
- NCT05932290
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05930925
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
Phase 2
Active, not recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT05926960
- Locations
- 🇩🇪
Universitaetsklinikum Tuebingen, Tübingen, Baden-württemberg, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
🇩🇪Universitaetsklinikum Essen, Essen, Nordrhein-westfalen, Germany
BESPONSA Injection 1 mg Special Investigation
Completed
- Conditions
- Acute Lymphocytic Leukemia
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 421
- Registration Number
- NCT05923112
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Single dose of PF-07220060 as first Tablet FormulationDrug: Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administrationDrug: Single dose of PF-07220060 as third tablet formulationDrug: Single dose of PF-07220060 as second Tablet FormulationDrug: Single dose of PF-07220060 as a Tablet Formulation
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT05923411
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1300
- Registration Number
- NCT05912933
© Copyright 2025. All Rights Reserved by MedPath